Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

📅 Published: September 23, 2026 | 📂 Category: Tech

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.


📱 Share on WhatsApp 🌐 View Original Article

Leave a Reply

Your email address will not be published. Required fields are marked *